Business · India Bureau
Cipla's Pune Manufacturing Unit Loses Drug Sales Licence
Regulatory authorities have cancelled the pharmaceutical licence of Cipla's Pune facility following inspection findings of multiple compliance violations. The action underscores ongoing scrutiny of manufacturing standards across India's pharmaceutical sector.
LSN India ·
Cipla Limited's drug manufacturing and sales licence at its Pune unit has been cancelled by regulatory authorities due to serious irregularities detected during inspection, according to official notifications. The cancellation marks a significant compliance action against one of India's largest pharmaceutical manufacturers.
The inspection uncovered multiple violations including unauthorised advertising of pharmaceutical products, improper storage and maintenance of medicines, and deficiencies in stock record-keeping procedures. Additionally, the facility failed to comply with mandatory product recall protocols, raising concerns about drug safety and traceability practices.
The irregularities suggest systematic lapses in adherence to Good Manufacturing Practice (GMP) standards and regulatory guidelines that govern India's pharmaceutical industry. Such findings typically trigger regulatory action to prevent compromised medicines from reaching consumers.
Cipla, headquartered in Mumbai, is among India's top pharmaceutical companies with a significant domestic and international presence. The company has not yet issued a public response regarding the licence cancellation. Industry observers note that such actions, while necessary for maintaining drug quality standards, can impact production capacity and supply chains for affected therapeutic categories.